Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  radium ra 223 dichloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-23 of 23 for your search:
Start Over
Radium-223 Dichloride Long-term Follow-up Program
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16996, 2014-002407-25, NCT02312960
Radium-223 Dichloride (Ra-223 Cl2) Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15397, NCT01810770
Phase III Radium 223 mCRPC-PEACE III
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1333, 2014-001787-36, NCT02194842
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Other
Protocol IDs: 2012-0952, NCI-2013-02267, NCT01833520
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16507, 2013-003118-42, NCT02023697
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16544, NCT02034552
Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI68770, NCT02199197
Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 17096, 2014-002114-23, NCT02258451
Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer
Phase: Phase II
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-098, c13-124, NCT02278055
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG 301, NCT02283749
A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-375, ONC-2013-119, NCT02346526
Phase II Trial of Ra-223 Dichloride and Hormonal Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0508, NCI-2015-00508, NCT02366130
Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-001070-34, 2014/2110, NCT02390934
A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: J1513, IRB00058873, NCT02396368
Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-523, NCT02406521
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
Phase: Phase I
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 17110, 2015-000083-34, NCT02442063
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16913, NCT02141438
Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Pro00053925, NCT02204943
A Drug Utilization Study of Radium-223 in Sweden
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 17399, NCT02331303
Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases
Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 17550, XF1412DE, NCT02398526
Start Over